IGF-1 LR3: Mechanism of Action

Introduction

IGF-1 LR3 is a synthetic analog of insulin-like growth factor-1 (IGF-1) that engages the type 1 IGF receptor (IGF-1R) while exhibiting markedly reduced affinity for the IGF-binding protein (IGFBP) family. These two properties — high-fidelity receptor engagement and minimal binding-protein sequestration — combine to make it a uniquely useful tool for interrogating IGF-1R pharmacology in experimental systems. This article summarizes the reported molecular pharmacology of IGF-1 LR3 as documented in the peer-reviewed literature. Research-grade IGF-1 LR3 from SpartaLabs is verified by independent third-party analytical testing prior to release.

Receptor Target and Binding Pathway

The primary cellular target of IGF-1 LR3 is IGF-1R, a transmembrane receptor tyrosine kinase belonging to the insulin receptor superfamily. IGF-1R exists as a disulfide-linked heterotetrameric complex composed of two extracellular alpha subunits and two membrane-spanning beta subunits. Ligand binding to the alpha-subunit extracellular domain — specifically to the leucine-rich L1 and cysteine-rich CR regions — induces a conformational transition that activates the intracellular beta-subunit kinase domains [1].

Structural analyses, including cryo-electron microscopy characterizations published by multiple groups, have resolved the binding site in detail. The alpha subunits of the IGF-1R dimer adopt an asymmetric, gamma-shaped configuration upon ligand engagement, with a single ligand molecule bridging binding sites contributed by each protomer [1]. IGF-1 LR3, by virtue of its conserved core sequence corresponding to native IGF-1, engages IGF-1R at the same binding interface as the endogenous ligand.

At concentrations substantially exceeding those needed for IGF-1R half-maximal activation, IGF-1 LR3 has been reported to engage the insulin receptor (IR) and heterotetrameric IGF-1R/IR hybrid receptors. Andersen and colleagues (2007) reported that in HEK293 cell cultures, Long R3IGF-I activated IR signaling at lower concentrations than the molecule's low inherent IR affinity would predict alone, an observation the authors attributed to the presence of hybrid receptor complexes [2]. This cross-receptor activity profile informs experimental design considerations for studies where IR pathway isolation is a requirement.

Role of Reduced IGFBP Affinity in Receptor Access

A mechanistic feature that distinguishes IGF-1 LR3 from native IGF-1 in experimental systems is the consequence of its substantially reduced IGFBP-binding affinity. In physiological contexts, the large majority of circulating IGF-1 is sequestered within high-affinity complexes — primarily the ternary 150 kDa complex of IGF-1 with IGFBP-3 and the acid-labile subunit (ALS). These complexes cannot traverse capillary walls and function as a circulating reservoir of the ligand largely inaccessible to cellular receptors on rapid timescales [3].

Because IGFBPs bind native IGF-1 with affinity equal to or exceeding that of IGF-1R itself, a significant fraction of added native IGF-1 in IGFBP-replete systems is sequestered before reaching the receptor. IGF-1 LR3, with its affinity for IGFBPs reduced by at least three orders of magnitude [4], exists predominantly as free peptide under conditions where native IGF-1 would be substantially bound. This differential sequestration profile means that a given mass of IGF-1 LR3 presents a proportionally larger free-peptide fraction available for receptor engagement — a property that makes it a more efficient and reproducible tool for receptor pharmacology investigations.

Tomas and colleagues (1996) quantified this in vivo, reporting that IGF-1 LR3 was approximately 2.5-fold more potent than native IGF-1 in growth and anti-catabolic assays in rat models, with this potency advantage maintained whether the compounds were administered by continuous infusion or single injection [4]. The specific study outcomes from this and related pharmacokinetic work are catalogued in the IGF-1 LR3 published research article.

Plasma clearance studies in rats further documented that LR3IGF-I is cleared more rapidly from circulation than native IGF-1 under normal IGFBP-replete conditions, consistent with the understanding that native molecule ternary complex formation slows its elimination [5]. In pregnant rats — where IGFBP-3 concentrations are naturally low — the clearance differential between IGF-1 and IGF-1 LR3 was substantially diminished, providing pharmacokinetic confirmation of the IGFBP-binding mechanism underlying the pharmacokinetic difference [5].

Reported Downstream Signaling Events

Following IGF-1R engagement by IGF-1 LR3, the activated receptor beta-subunit kinase domain trans-autophosphorylates multiple tyrosine residues within the activation loop, establishing a high-activity catalytic state. The principal cytoplasmic substrates of activated IGF-1R are the insulin receptor substrate (IRS) family proteins, particularly IRS-1 and IRS-2, which become tyrosine phosphorylated at multiple docking sites [6].

IRS phosphorylation initiates two major parallel signaling cascades documented in the literature:

PI3K/Akt pathway. Phosphorylated IRS recruits and activates class I phosphoinositide 3-kinase (PI3K), which catalyzes conversion of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3) at the inner leaflet of the plasma membrane. PIP3 recruits Akt (protein kinase B) to the membrane, where PDK1 and mTORC2 phosphorylate and activate it. Activated Akt phosphorylates multiple substrates associated with cell survival and protein synthesis, including mTORC1 activators and the pro-apoptotic protein BAD [6].

MAPK/ERK pathway. Tyrosine-phosphorylated IRS and the adaptor protein Shc recruit the Grb2-SOS complex, initiating guanine nucleotide exchange on Ras GTPase. Activated Ras engages the Raf-MEK-ERK kinase cascade, ultimately leading to phosphorylation of ERK1 and ERK2 (p44/42 MAPK) and their nuclear translocation [6].

Studies employing IGF-1 LR3 directly as the stimulant have confirmed engagement of both pathways. Jonker and colleagues (2003) reported that in fetal sheep cardiomyocytes stimulated with Long R3 IGF-1 in vitro, pharmacological inhibition of either ERK signaling or PI3K signaling completely abolished observed DNA synthesis (BrdU incorporation), indicating that both the MAPK/ERK and PI3K/Akt pathways were required for the observed response in that cell type and experimental context [7].

Andersen and colleagues (2007) reported that in HEK293 cells, Long R3IGF-I activated IGF-1R and IR to a greater extent at lower concentrations than native IGF-1, consistent with the free-peptide availability hypothesis, and that receptor phosphorylation preceded downstream Akt and ERK phosphorylation in the observed signaling sequence [2].

Active Research Frontiers

Several aspects of IGF-1 LR3 pharmacology represent open and productive areas of investigation in the published literature.

The pharmacological consequence of the 13-amino acid N-terminal extension is an active question. The extension reduces IGFBP affinity, but whether it contributes independently to receptor binding geometry or signaling bias at IGF-1R — beyond the E3R substitution — remains to be established by structural studies specific to the LR3 analog. Resolving this would clarify the relative contributions of each modification and could inform future analog design.

The degree to which mechanistic data generated in vitro and in short-duration animal infusion models translate to other tissue types, exposure durations, or species is an area of ongoing characterization. The GH-secretagogue CJC-1295 with DAC represents a complementary mechanistic angle on the GH/IGF axis, acting upstream at the level of growth hormone secretion rather than at the IGF-1 receptor directly. Published studies in bovine embryos, fetal sheep, guinea pigs, and human cell lines each capture distinct facets of IGF-1 LR3 pharmacology, and the integration of these findings across models continues to advance the field.

Receptor regulation dynamics for IGF-1 LR3, relative to native IGF-1, offer additional research opportunities. Published data suggest that IGF-1 LR3 and native IGF-1 differentially regulate IGF-1R mRNA abundance — with native IGF-1 associated with receptor mRNA reduction and the LR3 analog associated with receptor mRNA elevation in at least one bovine embryo model [8]. The mechanistic basis of this differential regulation, and its implications for sustained receptor engagement in experimental systems, is an open question with relevance to cell-culture protocol design.

References

1. Xu Y, Kong GK, Craig PJ, et al. Structural basis of the activation of type 1 insulin-like growth factor receptor. Nat Commun. 2019;10(1):4567. PMID: 31594955. PMC: PMC6783537. DOI: 10.1038/s41467-019-12564-0

2. Andersen DC, Storling J, Lindberg AM, et al. LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. Mol Biotechnol. 2007;34(2):201-12. PMID: 17172665. DOI: 10.1385/MB:34:2:201

3. Allard JB, Duan C. IGF-binding proteins: why do they exist and why are there so many? Front Endocrinol (Lausanne). 2018;9:117. PMID: 29686647. PMC: PMC5900387. DOI: 10.3389/fendo.2018.00117

4. Tomas FM, Lemmey AB, Read LC, Ballard FJ. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J Endocrinol. 1996;150(1):77-84. PMID: 8708565. DOI: 10.1677/joe.0.1500077

5. Fielder PJ, Mortensen DL, Mallet P, Carlsson B, Baxter RC, Clark RG. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats. Growth Regul. 1996;6(1):35-43. PMID: 7693845

6. Werner H. The IGF1 signaling pathway: from basic concepts to therapeutic opportunities. Cells. 2023;12(18):2222. PMID: 37759449. PMC: PMC10573540. DOI: 10.3390/cells12182222

7. Jonker SS, Zhang L, Louey S, Giraud GD, Thornburg KL, Faber JJ. Myocyte enlargement, differentiation, and proliferation kinetics in the fetal sheep heart. J Appl Physiol. 2003;94(6):2257-64. PMID: 12947030. DOI: 10.1152/japplphysiol.00828.2002

8. Sirisathien S, Hernandez-Fonseca HJ, Bosch P, et al. Insulin-like growth factor I (IGF-I) and long R(3)IGF-I differently affect development and messenger ribonucleic acid abundance for IGF-binding proteins and type I IGF receptors in in vitro produced bovine embryos. Domest Anim Endocrinol. 2001;20(1):57-72. PMID: 11181549. DOI: 10.1016/s0739-7240(00)00096-x